TY - JOUR
T1 - Hypocomplementemia (C3) as an independent predictor for children with acute post-streptococcal glomerulonephritis
T2 - A long-term observation
AU - Han, K. H.
AU - Lee, K. H.
AU - Park, S. J.
AU - Yu, R.
AU - Kim, S. H.
AU - Lee, I. R.
AU - Han, S. Y.
AU - Kim, H. S.
AU - Kronbichler, A.
AU - Li, H.
AU - Koyanagi, A.
AU - Jacob, L.
AU - Shin, Jae Il
AU - Kim, Ji Hong
AU - Smith, L.
N1 - Publisher Copyright:
© 2021 Verduci Editore s.r.l. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Objective: The aim of this study was to examine the altering patterns in clinical characteristics and severity of acute post-streptococcal glomerulonephritis (APSGN) in children. Patients and Methods: We analyzed the medical records of 119 children who were diagnosed with APSGN from 1987 to 2018, retrospectively. The patients were divided into two groups: Group I (n=72, before 1998) and Group II (n=47, after 1998). Clinical, radiologic, and laboratory findings were compared between the two groups. Results: The clinical manifestations, including vomiting (20.8% vs. 4.3%, p=0.014), oliguria (40.3% vs. 19.1%, p=0.016), and generalized edema (86.1% vs. 63.8%, p=0.005), were statistically less frequent since 1998. Pulmonary edema on chest X-ray (22.7% vs. 4.4%, p=0.014) was less frequent in Group II than in Group I. The level of BUN (23.3±19.3 vs. 18.8±11.2, p=0.009) was lower in Group II than in Group I, while that of creatinine was not significantly different between the two groups. C3 level was an independent factor for predicting the development of edema (odds ratio [OR]: 1.034, 95% CI: 1.010-1.060, p=0.006) and acute nephritic symptoms (≥2) (OR: 0.974, 95% CI: 0.952-0996, p=0.020). It was also negatively correlated with an increasing number of acute nephritic symptoms, including oliguria and edema, in patients with APSGN (R=.0.182, p=0.048). Conclusions: This study demonstrated that APSGN had favorable clinical manifestations and severity over the past 30 years. The monitoring of C3 levels can be used to assess the disease severity and risk of complications, including edema and oliguria, which are decreasing in South Korean children.
AB - Objective: The aim of this study was to examine the altering patterns in clinical characteristics and severity of acute post-streptococcal glomerulonephritis (APSGN) in children. Patients and Methods: We analyzed the medical records of 119 children who were diagnosed with APSGN from 1987 to 2018, retrospectively. The patients were divided into two groups: Group I (n=72, before 1998) and Group II (n=47, after 1998). Clinical, radiologic, and laboratory findings were compared between the two groups. Results: The clinical manifestations, including vomiting (20.8% vs. 4.3%, p=0.014), oliguria (40.3% vs. 19.1%, p=0.016), and generalized edema (86.1% vs. 63.8%, p=0.005), were statistically less frequent since 1998. Pulmonary edema on chest X-ray (22.7% vs. 4.4%, p=0.014) was less frequent in Group II than in Group I. The level of BUN (23.3±19.3 vs. 18.8±11.2, p=0.009) was lower in Group II than in Group I, while that of creatinine was not significantly different between the two groups. C3 level was an independent factor for predicting the development of edema (odds ratio [OR]: 1.034, 95% CI: 1.010-1.060, p=0.006) and acute nephritic symptoms (≥2) (OR: 0.974, 95% CI: 0.952-0996, p=0.020). It was also negatively correlated with an increasing number of acute nephritic symptoms, including oliguria and edema, in patients with APSGN (R=.0.182, p=0.048). Conclusions: This study demonstrated that APSGN had favorable clinical manifestations and severity over the past 30 years. The monitoring of C3 levels can be used to assess the disease severity and risk of complications, including edema and oliguria, which are decreasing in South Korean children.
UR - http://www.scopus.com/inward/record.url?scp=85116166535&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116166535&partnerID=8YFLogxK
U2 - 10.26355/eurrev_202109_26786
DO - 10.26355/eurrev_202109_26786
M3 - Article
C2 - 34604959
AN - SCOPUS:85116166535
SN - 1128-3602
VL - 25
SP - 5674
EP - 5683
JO - European Review for Medical and Pharmacological Sciences
JF - European Review for Medical and Pharmacological Sciences
IS - 18
ER -